BillionToOne told investors it expects Unity Confirm to drive further gains in its prenatal testing franchise. The company said the circulating fetal cell-based confirmatory assay is designed to enable confirmation of high-risk screening results without invasive follow-up like CVS or amniocentesis. Management indicated that Unity Confirm volumes should remain small because less than 1% of screened patients are expected to test positive, but it could increase adoption of its Unity Aneuploidy screening platform since only patients screened with Unity Aneuploidy would be eligible for Unity Confirm. The update builds on a strong Q1 performance, as BillionToOne reported a sharp revenue jump tied to increased prenatal clinical testing volume and continued growth in oncology testing and other services.